Suspected side effects of swine flu antiviral Tamiflu can now be reported to the Medicines and Healthcare products Regulatory Agency via a new dedicated webpage.
The system, based on the Yellow Card Scheme, is designed to make completing a report quick and easy healthcare professionals. The system will assist the MHRA in monitoring the safety of the swine flu antiviral medicines, Tamiflu and Relenza, as their use increases during the swine flu pandemic.
Dr June Raine, MHRA director of vigilance and risk management of medicines, said Tamiflu and Relenza are acceptably safe and most people will not suffer any side effects.
‘Like all medicines, the MHRA keeps the safety of these continually under review and we are keen to let people know there is a new way to tell us of any side effect suspicions.
‘By providing this information, not only are the MHRA able to gain better insights into the safety of medicines, but nurses can directly contribute to effective medicines regulation.’